These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 34050793)

  • 41. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
    Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
    Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.
    Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W
    Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.
    Labrador-Horrillo M; Martinez MA; Selva-O'Callaghan A; Trallero-Araguas E; Balada E; Vilardell-Tarres M; Juárez C
    J Immunol Res; 2014; 2014():290797. PubMed ID: 24741583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis.
    Wongjirattikarn R; Chaowattanapanit S; Choonhakarn C; So-Ngern A; Mahakkanukrauh A; Foocharoen C
    Case Rep Dermatol; 2020; 12(1):57-63. PubMed ID: 32308577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
    Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
    Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis.
    So J; So H; Wong VT; Ho R; Wu TY; Wong PC; Tam LH; Ho C; Lam TT; Chung YK; Li WL; To CH; Lau CS; Mok CC; Tam LS
    Rheumatology (Oxford); 2022 Nov; 61(11):4437-4444. PubMed ID: 35157042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    J Rheumatol; 2017 Mar; 44(3):319-325. PubMed ID: 28089977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
    Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
    Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
    Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
    Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
    Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
    Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic flare and cutaneous ulceration following cytomegalovirus infection in a patient with anti-melanoma differentiation-associated protein 5 (MDA5) associated myositis: Diagnostic challenge during the time of coronavirus disease (COVID-19) pandemic.
    Gupta P; Kharbanda R; Lawrence A; Gupta L
    Egypt Rheumatol; 2021 Oct; 43(4):271-274. PubMed ID: 36536808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-MDA5 Antibody Spectrum in Western World.
    Moghadam-Kia S; Oddis CV; Aggarwal R
    Curr Rheumatol Rep; 2018 Oct; 20(12):78. PubMed ID: 30382445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
    Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
    Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study.
    Zhou S; Lai J; Wu C; Liu Y; Liu Y; Zhao J; Xu D; Tian X; Li M; Zhao Y; Wang Y; Wang Q; Zeng X
    Front Immunol; 2022; 13():928861. PubMed ID: 35983058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
    Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
    McPherson M; Economidou S; Liampas A; Zis P; Parperis K
    Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
    Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.